TC BioPharm (Holdings) plc Warrants
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat … Read more
TC BioPharm (Holdings) plc Warrants (TCBPW) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2024: -1.364x
Based on the latest financial reports, TC BioPharm (Holdings) plc Warrants (TCBPW) has a cash flow conversion efficiency ratio of -1.364x as of September 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.73 Million) by net assets ($2.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
TC BioPharm (Holdings) plc Warrants - Cash Flow Conversion Efficiency Trend (2019–2023)
This chart illustrates how TC BioPharm (Holdings) plc Warrants's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
TC BioPharm (Holdings) plc Warrants Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of TC BioPharm (Holdings) plc Warrants ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ODINWELL AB
F:0AF
|
N/A |
|
LSEB Creative Corp.
OTCQB:LSEB
|
2.431x |
|
AKER -A-
BE:FKM
|
N/A |
|
GDO
F:GDO
|
-0.280x |
|
AMADEUS IT HOLD -A-
BE:AI3A
|
0.093x |
|
Stone Gold Inc.
PINK:STGDF
|
-0.022x |
|
ARCHER-DANIELS MID.
MU:ADM
|
0.021x |
|
Bravo Multinational Inc
PINK:BRVO
|
0.024x |
Annual Cash Flow Conversion Efficiency for TC BioPharm (Holdings) plc Warrants (2019–2023)
The table below shows the annual cash flow conversion efficiency of TC BioPharm (Holdings) plc Warrants from 2019 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $2.69 Million | $-10.54 Million | -3.927x | +91.49% |
| 2022-12-31 | $331.26K | $-15.29 Million | -46.163x | -13796.79% |
| 2021-12-31 | $-16.56 Million | $-5.58 Million | 0.337x | -67.13% |
| 2020-12-31 | $-3.35 Million | $-3.43 Million | 1.025x | -61.31% |
| 2019-12-31 | $-2.54 Million | $-6.73 Million | 2.650x | -- |